Filings & corporate actions
44 results filed
CSVNext results · Q2 FY27
Expected 29 Oct 2026 – 11 Nov 2026
Estimate: filed 29–42 days after quarter end, last 5 times
Dividend
₹0.50 per share · last 1 Jul 2022
2026
- 5 AugresultsResults · Q1 FY27 · consolidated and standalone+0.1%NSE
- 21 JulshareholdingShareholding · 30 Jun 2026-1.8%NSE
- 28 MayresultsResults · Q4 FY26 · consolidated and standalone+5.0%NSE
- 14 AprshareholdingShareholding · 31 Mar 2026+3.1%NSE
- 28 JanresultsResults · Q3 FY26 · consolidated and standalone-2.9%NSE
- 17 JanshareholdingShareholding · 31 Dec 2025-0.8%NSE
Reaction to results · all yearsrose on day 0 in 17 of 43 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 5 Aug 2026 | +0.1% | -0.7% | +6.7% | 1.4× |
| Q4 FY26 | 28 May 2026 | +5.0% | -2.8% | -5.5% | 1.4× |
| Q3 FY26 | 28 Jan 2026 | -2.9% | -4.6% | -18.3% | 0.3× |
| Q2 FY26 | 11 Nov 2025 | -5.2% | -10.0% | -18.8% | 4.7× |
| Q1 FY26 | 5 Aug 2025 | +1.0% | +3.3% | -0.7% | 1.9× |
| Q4 FY25 | 30 May 2025 | +6.1% | +9.7% | +0.1% | 9.7× |
| Q3 FY25 | 10 Feb 2025 | -4.2% | -23.3% | +6.9% | 0.6× |
| Q2 FY25 | 5 Nov 2024 | -3.4% | -16.9% | -6.5% | 2.0× |
| Q1 FY25 | 2 Aug 2024 | -5.6% | -4.4% | -8.8% | 1.1× |
| Q4 FY24 | 29 May 2024 | -4.0% | -22.1% | -12.7% | 11.7× |
| Q3 FY24 | 9 Feb 2024 | -6.2% | +6.0% | -11.5% | 8.8× |
| Q2 FY24 | 2 Nov 2023 | -3.3% | -2.6% | -2.8% | 2.3× |
| Q1 FY24 | 3 Aug 2023 | -7.1% | -5.7% | -11.2% | 6.0× |
| Q4 FY23 | 29 May 2023 | -7.4% | -11.0% | -13.0% | 2.6× |
| Q3 FY23 | 1 Feb 2023 | -4.8% | +0.8% | +1.1% | 2.7× |
| Q2 FY23 | 5 Nov 2022 | +1.3% | -2.8% | -5.3% | 3.3× |
| Q1 FY23 | 3 Aug 2022 | +1.4% | -3.5% | +42.2% | 5.1× |
| Q4 FY22 | 24 May 2022 | -2.5% | -5.2% | -18.3% | 0.9× |
| Q3 FY22 | 9 Feb 2022 | -2.0% | -7.1% | -8.2% | 0.6× |
| Q2 FY22 | 29 Oct 2021 | +4.1% | +1.6% | -4.4% | 0.7× |
| Q1 FY22 | 17 Jul 2021 | +5.0% | -3.9% | -9.0% | 1.9× |
| Q4 FY21 | 21 May 2021 | +2.9% | +16.7% | 0.0% | 3.6× |
| Q3 FY21 | 20 Jan 2021 | -3.1% | -18.1% | -8.3% | 0.8× |
| Q2 FY21 | 13 Oct 2020 | +5.0% | -0.8% | -23.9% | 1.0× |
| Q1 FY21 | 22 Jul 2020 | +5.0% | +33.9% | +80.2% | 0.5× |
| Q4 FY20 | 17 Jun 2020 | +2.1% | +9.4% | +20.9% | 4.1× |
| Q3 FY20 | 14 Feb 2020 | +7.3% | -3.4% | -29.2% | 0.8× |
| Q2 FY20 | 29 Oct 2019 | -1.9% | -1.9% | -4.3% | 6.1× |
| Q1 FY20 | 9 Aug 2019 | +4.9% | +21.9% | +29.9% | 1.0× |
| Q4 FY19 | 7 May 2019 | +5.0% | -0.6% | -19.3% | 0.1× |
| Q3 FY19 | 7 Feb 2019 | +5.3% | +33.3% | +175.4% | 1.0× |
| Q2 FY19 | 20 Nov 2018 | 0.0% | +21.1% | +150.0% | 0.0× |
| Q1 FY19 | 23 Aug 2018 | 0.0% | 0.0% | +105.0% | 0.1× |
| Q4 FY18 | 25 May 2018 | 0.0% | +10.2% | +103.4% | 0.2× |
| Q3 FY18 | 13 Mar 2018 | -1.7% | +3.3% | +91.7% | 0.0× |
| Q2 FY18 | 20 Nov 2017 | 0.0% | 0.0% | +14.0% | 0.1× |
| Q1 FY18 | 1 Sept 2017 | -5.0% | -25.0% | -26.2% | 0.0× |
| Q4 FY17 | 13 May 2017 | -2.8% | +23.6% | +91.7% | 0.1× |
| Q3 FY17 | 30 Jan 2017 | -2.7% | -13.5% | +39.2% | 0.1× |
| Q2 FY17 | 14 Nov 2016 | -4.5% | +14.9% | +4.5% | 0.0× |
| Q1 FY17 | 6 Aug 2016 | -3.7% | -3.7% | -13.6% | 1.0× |
| Q4 FY16 | 28 May 2016 | +4.6% | +26.2% | +23.1% | 1.8× |
| Q3 FY16 | 13 Feb 2016 | -10.0% | 0.0% | -30.0% | 1.6× |
| Average | -0.7% | +1.0% | +15.7% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+14.1%
Profit YoY+347.6%
Interest cost YoY—
Revenue QoQ+14.1%
Profit QoQ+111.7%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
CSVOpen23.00
Day range22.32 – 23.00
52-week range15.20 – 45.34
From 52w high-50.0%
RSI (14)45.1
ATR (14)1.21
Volume8.4K
Avg volume (20D)33.2K
Rel volume0.25×
Volatility (1Y)47.3%
Turnover₹1.9L
SMA 50 / 20023.49 / 23.80
Delivery percentage
Latest · 6 Oct 202674.7%
20-day avg73.2%
1-year avg77.8%
Percentile (own history)69th
Range4.1–100.0%
Sessions1,731
Over the last 20 sessions BALAXI settled 73.2% of its traded quantity, which is unusually high for an NSE equity. Its one-year average is 77.8%, so recent sessions are running 4.6 points lower than usual. The latest session ranks higher than 69% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | -0.44% | +1.25% | -12.13% | -4.95% | +7.34% | -47.46% |
Valuation
CSVMarket cap₹125 Cr
P/E (TTM)51.6
EPS (TTM)0.44
Shares outstanding5.52Cr
Listed30 Nov 2015
Ownership
CSVPromoter65.99%
Promoter Δ QoQ0.00 pp
Public34.01%
FII0.00%
DII2.56%
Pledged0.00%
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 56.2 | 72.5 | 70.7 | 80.7 |
| YoY chg | — | — | -7.3% | +14.1% |
| Net profit (₹ Cr) | 0.2 | 0.3 | 0.6 | 1.3 |
| YoY chg | — | — | -92.9% | +347.6% |
| Net margin | 0.4% | 0.4% | 0.9% | 1.6% |
| EPS | 0.04 | 0.06 | 0.11 | 0.24 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 65.99% · public 34.01%2021-092026-06
- Promoter
- Public and others
- Promoter
- 65.99%
- Public
- 34.01%
- Promoter change
- 0.00 pp
- Filed
- 21 Jul 2026
- FII
- 0.00%
- DII
- 2.56%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26AR | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 54.7 | 60.8 | 59.8 | 65.6 | 77.4 | 73.3 | 76.3 | 70.7 | 56.2 | 72.5 | 70.7 | 80.7 | |
| Other income | 0.3 | (0.1) | (1.8) | (1.8) | (4.1) | 3.9 | (1.7) | (1.8) | 1.6 | 0.1 | 2.9 | (1.0) | |
| Total income | 55.0 | 60.7 | 58.0 | 63.8 | 73.3 | 77.2 | 74.6 | 69.0 | 57.8 | 72.6 | 73.6 | 79.7 | |
| Total expenses | 45.0 | 48.0 | 47.6 | 56.4 | 67.7 | 71.2 | 64.9 | 68.1 | 56.4 | 71.0 | 72.2 | 77.6 | |
| └ Finance costs | 0.4 | 0.4 | 0.6 | 0.4 | 0.5 | 1.4 | 0.7 | 1.0 | 0.9 | 1.0 | 1.0 | 0.7 | |
| └ Depreciation | 0.7 | 0.5 | 0.7 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.8 | |
| Profit before tax | 15.7 | 14.3 | 11.5 | 7.4 | 5.6 | 6.1 | 9.7 | 0.9 | 1.4 | 1.6 | 1.4 | 2.1 | |
| Tax expense | 1.2 | 0.7 | 0.6 | 0.9 | 1.0 | 0.7 | 1.0 | 0.6 | 1.2 | 1.3 | 0.8 | 0.8 | |
| Net profit | 14.4 | 13.6 | 10.9 | 6.5 | 4.6 | 5.4 | 8.6 | 0.3 | 0.2 | 0.3 | 0.6 | 1.3 | |
| EPS | 2.82 | 2.66 | 2.08 | 1.17 | 0.84 | 0.97 | 1.56 | 0.05 | 0.04 | 0.06 | 0.11 | 0.24 | |
| Net margin | 26.37% | 22.36% | 18.27% | 9.88% | 5.93% | 7.32% | 11.33% | 0.41% | 0.37% | 0.42% | 0.87% | 1.61% | |
| PBT margin | 28.62% | 23.48% | 19.21% | 11.24% | 7.19% | 8.28% | 12.67% | 1.28% | 2.45% | 2.22% | 1.98% | 2.59% | |
| Tax rate | 7.87% | 4.76% | 4.87% | 12.13% | 17.50% | 11.64% | 10.61% | 67.90% | 84.82% | 81.05% | 56.31% | 37.90% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 5 Aug 2026.
BALAXI at a glance
- BALAXI closed at ₹22.67 on 6 Oct 2026, -0.44% on the day, -47.5% over one year, 50.0% below its 52-week high of ₹45.34.
- Delivery was 74.7% of traded quantity on 6 Oct 2026, the 69th percentile of its own 1,731 sessions with a reading (20-session average 73.2%, 1-year average 77.8%).
- Market capitalisation is ₹125 crore at a trailing P/E of 51.6 (trailing EPS ₹0.44).
- Q1 FY27 results (consolidated, filed 5 Aug 2026): revenue ₹81 crore (+14.1% year on year), net profit ₹1 crore (+347.6%); the price moved +0.1% on the first session after.
- Promoters held 65.99% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 29 Oct 2026 and 11 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE618N01022
SeriesEQ
Listed30 Nov 2015
History from1 Dec 2015
Sessions2,156
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE